日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

TOURMALINE-MM3 和 -MM4 随机对照试验中伊沙佐米维持治疗新诊断多发性骨髓瘤的最终总生存期分析

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01411-9
Dimopoulos, Meletios A; Lonial, Sagar; Chng, Wee-Joo; Iida, Shinsuke; Mateos, María-Victoria; Morgan, Gareth J; Li, Cong; Byrne, Catriona; Suryanarayan, Kaveri; Labotka, Richard; Rajkumar, S Vincent
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

联合人工智能驱动的事件预测和纵向建模在初诊和复发性多发性骨髓瘤中的应用

期刊:npj Digital Medicine
影响因子:15.1
doi:10.1038/s41746-024-01189-3
Hussain, Zeshan; De Brouwer, Edward; Boiarsky, Rebecca; Setty, Sama; Gupta, Neeraj; Liu, Guohui; Li, Cong; Srimani, Jaydeep; Zhang, Jacob; Labotka, Rich; Sontag, David
骨髓瘤
多发性骨髓瘤
发表日期：2024
文献求助 收藏

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone

在TOURMALINE-MM1研究中，调整后续治疗后发现，在来那度胺和地塞米松的基础上加用伊沙佐米可显著改善总生存期。

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2023.283713
Ramasamy, Karthik; Bahlis, Nizar J; Kumar, Shaji K; Kumar, Arun; Cranmer, Holly; Wang, Bingxia; Dabora, Jonathan; Labotka, Richard; Richardson, Paul G; Moreau, Philippe
多发性骨髓瘤
发表日期：2024
文献求助 收藏

Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone

建立血清M蛋白反应模型，用于早期检测接受硼替佐米、来那度胺和地塞米松治疗的多发性骨髓瘤患者的生化复发

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13225
Otani, Yuki; Zhao, Yunqi; Wang, Guanyu; Labotka, Richard; Rogge, Mark; Gupta, Neeraj; Vakilynejad, Majid; Bottino, Dean; Tanigawara, Yusuke
多发性骨髓瘤
骨髓瘤
发表日期：2024
文献求助 收藏

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

在 TOURMALINE-MM3 和 -MM4 试验中，对 1280 例多发性骨髓瘤患者进行维持治疗期间 MRD 动态变化分析，以改善预后。

期刊:Blood
影响因子:23.1
doi:10.1182/blood.2022016782
Paiva, Bruno; Manrique, Irene; Dimopoulos, Meletios A; Gay, Francesca; Min, Chang-Ki; Zweegman, Sonja; Špička, Ivan; Teipel, Raphael; Mateos, María-Victoria; Giuliani, Nicola; Cavo, Michele; Hopkins, Christine Rojas; Fu, Weijun; Suryanarayan, Kaveri; Vorog, Alexander; Li, Cong; Wang, Bingxia; Estevam, Jose; Labotka, Richard; Dash, Ajeeta B
骨髓瘤
多发性骨髓瘤
发表日期：2023
文献求助 收藏

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

一项根据细胞遗传学异常对接受伊沙佐米治疗与安慰剂治疗的多发性骨髓瘤患者预后进行汇总分析

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-022-00768-5
Chng, Wee-Joo; Lonial, Sagar; Morgan, Gareth J; Iida, Shinsuke; Moreau, Philippe; Kumar, Shaji K; Twumasi-Ankrah, Philip; Villarreal, Miguel; Dash, Ajeeta B; Vorog, Alexander; Zhang, Xiaoquan; Suryanarayan, Kaveri; Labotka, Richard; Dimopoulos, Meletios A; Rajkumar, S Vincent
多发性骨髓瘤
细胞生物学
骨髓瘤
发表日期：2023
文献求助 收藏

"It kinda has like a mind": Children's and parents' beliefs concerning viral disease transmission for COVID-19 and the common cold

“它好像有自己的想法”：儿童和家长对新冠病毒和普通感冒病毒传播的看法

期刊:Cognition
影响因子:2.8
doi:10.1016/j.cognition.2023.105413
Labotka, Danielle; Gelman, Susan A
微生物学
新冠
发表日期：2023
文献求助 收藏

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

在TOURMALINE-MM2试验中，新诊断的多发性骨髓瘤患者的晚期反应与早期反应和反应深度与改善预后相关。

期刊:eJHaem
影响因子:1.2
doi:10.1002/jha2.759
Richardson, Paul G; Facon, Thierry; Venner, Christopher P; Bahlis, Nizar J; Offner, Fritz; White, Darrell; Karlin, Lionel; Benboubker, Lotfi; Voog, Eric; Yoon, Sung-Soo; Suzuki, Kenshi; Shibayama, Hirohiko; Zhang, Xiaoquan; Villarreal, Miguel; Twumasi-Ankrah, Philip; Labotka, Richard; Rifkin, Robert M; Lonial, Sagar; Kumar, Shaji K; Rajkumar, S Vincent; Moreau, Philippe
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

口服伊沙佐米-地塞米松与口服泊马度胺-地塞米松治疗来那度胺耐药、既往接受过蛋白酶体抑制剂治疗的多发性骨髓瘤：一项随机 II 期试验

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-021-00593-2
Dimopoulos, Meletios A; Schjesvold, Fredrik; Doronin, Vadim; Vinogradova, Olga; Quach, Hang; Leleu, Xavier; Montes, Yolanda Gonzalez; Ramasamy, Karthik; Pompa, Alessandra; Levin, Mark-David; Lee, Cindy; Mellqvist, Ulf Henrik; Fenk, Roland; Demarquette, Hélène; Sati, Hamdi; Vorog, Alexander; Labotka, Richard; Du, Jichang; Darif, Mohamed; Kumar, Shaji
多发性骨髓瘤
骨髓瘤
发表日期：2022
文献求助 收藏

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients

利用关键性 III 期 TOURMALINE-MM1 研究的数据，对多发性骨髓瘤患者进行伊沙佐米疗效和安全性的群体药代动力学/药效学联合建模

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12815
Srimani, Jaydeep K; Diderichsen, Paul M; Hanley, Michael J; Venkatakrishnan, Karthik; Labotka, Richard; Gupta, Neeraj
多发性骨髓瘤
骨髓瘤
发表日期：2022
文献求助 收藏